domingo, 30 de junio de 2013

Triple therapy for new-onset diabetes: A paradigm shift?

Chicago, IL - A novel approach of starting newly diagnosed type 2 diabetes patients on three therapeutic agents simultaneously showed greater and more durable reductions in HbA1c, less hypoglycemia, and less weight gain compared with conventional, stepwise add-on treatment in a new study reported yesterday here at the American Diabetes Association (ADA) 2013 Scientific Sessions [1].

The results of this so-called "triple therapy," in this case metformin, pioglitazone, and the glucagonlike peptide-1 (GLP-1) agonist exenatide (Byetta, AstraZeneca/Bristol-Myers Squibb Alliance), were hailed as potentially revolutionary and possibly "paradigm shifting," although questions remain.
The comparator stepwise add-on regimen was with metformin, a sulfonylurea (glyburide), and basal insulin glargine.

No hay comentarios:

Publicar un comentario